65- Mariani M, McHugh M, Petrillo M et al
(2014) HGF/c-Met axis drives cancer aggres-
siveness in the neo-adjuvant setting of ovarian
cancer. Oncotarget 5:4855–4867 - Wu JG, Yu JW, Wu HB et al (2014) Expressions
and clinical significances of c-MET, p-MET
and E2f-1 in human gastric carcinoma. BMC
Res Notes 7:6 - Iveson T, Donehower RC, Davidenko I
(2014) Rilotumumab in combination with
epirubicin, cisplatin, and capecitabine as first-
line treatment for gastric or esophagogastric
junction adenocarcinoma: an open-label, dose
de-escalation phase 1b study and a double-
blind, randomised phase 2 study. Lancet Oncol
15:1007–1018 - Cunningham D, Tebbutt NC, Davidenko I
et al (2015) Phase III, randomized, double-
blind, multicenter, placebo (P)-controlled trial
of rilotumumab (R) plus epirubicin, cisplatin
and capecitabine (ECX) as first-line therapy
in patients (pts) with advanced MET-positive
(pos) gastric or gastresophageal junction (G/
GEJ) cancer: RILOMET-1 study. J Clin Oncol
33(Suppl):abstr 4000 - Shah MA, Bang YJ, Lordick F et al (2015)
METGastric: a phase III study of onartuzumab
plus mFOLFOX6 in patients with metastatic
HER2-negative (HER2−) andMET-positive
(MET+) adenocarcinoma of the stomach or
gastresophageal junction (GEC). J Clin Oncol
33(Suppl):abstract 4012 - Swann JB, Smyth MJ (2007) Immune surveil-
lance of tumors. J Clin Invest 17:1137–1146 - Keir ME, Butte MJ, Freeman GJ (et al) (2008)
PD-1 and its ligands in tolerance and immu-
nity. Annu Rev Immunol 26: 677–704 - Pardoll DM (2012) The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev
Cancer 12:252–264
46. Robert C, Schachter J, Long GV et al (2015)
Pembrolizumab versus ipilimumab in advanced
melanoma. N Engl J Med 372:2521–2532
47. Larkin J, Hodi FS, Wolchok JD (2015)
Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl
J Med 373:1270–1271
48. Motzer RJ, Escudier B, McDermott DF
et al (2015) Nivolumab versus everolimus in
advanced renal-cell carcinoma. N Engl J Med
373:1803–1813
49. Brahmer J, Reckamp KL, Baas P et al (2015)
Nivolumab versus docetaxel in advanced squa-
mous-cell non-small-cell lung cancer. N Engl
J Med 373:123–135
50. Borghaei H, Paz-Ares L, Horn L et al (2015)
Nivolumab versus docetaxel in advanced non-
squamous non-small-cell lung cancer. N Engl
J Med 373:1627–1639
51. Garon EB, Rizvi NA, Hui R et al (2015)
Pembrolizumab for the treatment of non-small-
cell lung cancer. N Engl J Med 372:2018–2028
52. Muro K, Chung HC, Shankaran V et al
(2016) Pembrolizumab for patients with
PD-L1-positive advanced gastric cancer
(KEYNOTE-012): a multicentre, open-label,
phase 1b trial. Lancet Oncol 17:717–726
53. Kang YK, Satoh, Ryu MH et al (2017)
Nivolumab (ONO-4538/BMS-936558) as
salvage treatment after second or later-line
chemotherapy for advanced gastric or gastro-
esophageal junction cancer (AGC): a double-
blinded, randomized, phase III trial. J Clin
Oncol 35(Suppl 4S):abstract 2
54. Janjigian YY, Bendell JC, Calvo et al (2016)
CheckMate-032: Phase I/II, open-label study
of safety and activity of nivolumab (nivo) alone
or with ipilimumab (ipi) in advanced and meta-
static (A/M) gastric cancer (GC). J Clin Oncol
34(Suppl):abstr 4010
Target Therapy of Esophageal Adenocarcinoma